

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
Sheet	1	of	2
		Application Number:	10/230,433 10/695,536
		Filing Date:	August 29, 2002
		First Named Inventor:	Iben Clifton Wells
		Group Art Unit:	1621
		Examiner Name:	Not Yet Assigned S. Kumar
		Attorney Docket Number:	2892-466 800F12-000f

U. S. PATENT DOCUMENTS

RECEIVED

FEB 28 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Signature	S. Kumar	Date Considered	7/16/03 4/21/04
-----------------------	----------	--------------------	-----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is available.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number:	10/230,133 0 695,536
		Filing Date:	August 29, 2002
		First Named Inventor:	Iberi Clifton Wells
		Group Art Unit:	1621
		Examiner Name:	Not Yet Assigned S. Kumar
		Attorney Docket Number:	2892106 800512-0008
Sheet	2	of	2


OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SL		ALTURA, B.M., and Altura, B.T., "Cardiovascular Risk Factors and Magnesium: Relationships to Atherosclerosis, Ischemic Heart Disease and Hypertension," <i>Magnes Trace Elem.</i> 1991-92, 10:182-192.	
SL		WELLS, IBERT C. and Blotcky, Alan J., "Coexisting independent sodium-sensitive and sodium-insensitive mechanisms of genetic hypertension in spontaneously hypertensive rats (SHR)," <i>Can. J. Physiol. Pharmacol.</i> 2001, 79: 779-784.	
SL		HOLVOET, PAUL, et al., "Stimulation with a Monoclonal Antibody (mAb4E4) of Scavenger Receptor-mediated Uptake of Chemically Modified Low Density Lipoproteins by THP-1-derived Macrophages Enhances Foam Cell Generation," <i>J. Clin. Invest.</i> , January 1994, 93: 89-98.	

Examiner Signature S. Kamm Date Considered 7/17/03 9/21/04

(Please copy or type the name) with their contact information as applicable.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. USE THE MAILING ADDRESS ON THE COVER SHEET.



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number:	10/230,433 10 695-S-36
Filing Date:	August 29, 2002
First Named Inventor:	Ibert Clifton Wells
Group Art Unit:	1621
Examiner Name:	Not Yet Assigned S. Kumpur
Attorney Docket Number:	2862-166 F008P12-0004
	RECEIVED JUN 09 2002 TECH CENTER 16

RECEIVED

JUN 09 2003

~~TECH CENTER 1600/2900~~

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	S. Kerner	Date Considered	7/16/03 9/21/04
-----------------------	-----------	--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002 OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Complete if Known

RECEIVED

JUN 09 2003

Substitute for Form 1449B/PTO (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number:	10/230,133 10/695,536
Filing Date:	August 29, 2002
First Named Inventor:	Ibert Clifton Wels
Group Art Unit:	1621
Examiner Name:	S. Kumar

JUN 09 2003

~~006~~ TECH CENTER 1600/2900

Examiner Signature	S. J. Curran	Date Considered	7/16/02	9/21/04
--------------------	--------------	-----------------	---------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		10	695-S-36	
				Application Number		09/635,288 PCTO 10/23/01		
				Filing Date		August 9, 2000 herewith 8/29/02		
				First Named Inventor		Ibert Clifton WELLS		
				Group Art Unit		1624 1621		
Examiner Name				K. Habte S. Kumar				
Sheet	1	of	1	Attorney Docket Number		W16-3 (N1427-002) 500812-0008		

U.S. PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				10/6/98 8:36	
				Application Number	09/635,266 New 10/20/02 8/29/02
				Filing Date	August 9, 2000 Received 8/29/02
				First Named Inventor	Ibert Clifton WELLS
Group Art Unit	162 162				
Examiner Name	S. Kumar				
Sheet	1	of	1	Attorney Docket Number	W16-3-(N1427-002) 2849-006
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
SL		EDVINSSON, L., et al., "Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man," <i>J. Human Hypertension</i> , 1989, 3:267-270.			
		FAULHABER, H.D., et al., "Substance P In Human Essential Hypertension," <i>J. Cardiovasc. Pharmacol.</i> , 1987, 10(Suppl. 12):S172-S176.			
		MEYER, P., and MARCHE, P., "Cell Membrane in Hypertension," <i>The American Journal of Medical Sciences</i> , April, 1988, 295(4):396-399.			
		MORI, K., et al., "Decreases in Substance P and Vasoactive Intestinal Peptide Concentrations in Plasma of Stroke-Prone Spontaneously Hypertensive Rats," <i>Jpn. Heart J.</i> , November, 1993, 34(6):785-794.			
		RESNICK, L.M., et al., "Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations," <i>Proc. Natl. Acad. Sci. USA</i> , October, 1984, 81:6511-6515.			
		SANFILIPPO, J.S., et al., "Amniotic Fluid Levels of Substance P," <i>The Journal of Reproductive Medicine</i> , August, 1992, 37(8):733-736.			
		TAKANO, Y., et al., "Substance P immunoreactivity released from rat spinal cord after kainic acid excitation of the ventral medulla oblongata: a correlation with increases in blood pressure," <i>Brain Research</i> , 1984, 291:168-172.			
Examiner Signature	<i>S. Kumar</i>		Date Considered	7/17/03 9/21/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	09/635,266 10 645536
Filing Date	August 9, 2000 8/12/00
First Named Inventor	Ibert Clifton WELLS
Group Art Unit	162
Examiner Name	S. Kurnio

Sheet 1 of 2 Attorney Docket Number W16-3 (N1427-002) ~~2008-106~~

U.S. PATENT DOCUMENTS

800812 - 0008

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
S. K.		5,268,359		Harmar et. al.	12-07-1993
		5,491,140		Brunn et al.	02-13-1996
		5,492,927		Gitter et al.	02-20-1996
		5,525,624		Gitter et al.	06-11-1996
		5,563,133		Hipskind	10-08-1996
		5,565,568		Cho et al.	10-15-1996
		5,594,022		Horwell et al.	01-14-1997
		5,607,947		Hipskind	03-04-1997
		5,610,176		Horwell et al.	03-11-1997
		5,616,562		Murphy et al.	04-01-1997
S. K.		5,670,499		Cho et al.	09-23-1997
S. K.		5,684,033		Cho et al.	11-04-1997
S. K.		5,698,710		Sisto et al.	12-16-1997

Examiner Signature

S. Kurnio

Date Considered

7/17/03 9/21/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB Indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Co... if Known 10) 695-536

Application Number	09/635,266 Rec'd 10-23-01				
Filing Date	August 9, 2000 Received 8/29/02				
First Named Inventor	Ibert Clifton WELLS				
Group Art Unit	161 162				
Examiner Name	S. Kumar				
Sheet	2	of	2	Attorney Docket Number	W16-3 (N1427-002) 200618-0008

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
GAC		FRICKEY, P.H., et al., "Preparation and Characterization of Monoclonal Antibodies to Substance P," <i>Hybridoma</i> , Nov. 6, 1991, 10:685-694.	
		HORWELL, D.C., "Use of the Chemical Structure of Peptides as the Starting Point to Design Nonpeptide Agonists and Antagonists at Peptide Receptors: Examples with Cholecystokinin and Tachykinins," <i>Bioorganic & Medicinal Chemistry</i> , 1996, 4(10):1573-1576.	
		MATTINGLY, M.T., et al. "Decreased Cell Membrane Magnesium in Some Essential Hypertension Patients," <i>Clin. and Exper. Hyper.-Theory and Practice</i> , 1991, 13:65-82 (author's reprint enclosed-total of 20 pages). (1)	
		THEODORSSON-NORHEIM, E., et al., "Neuropeptide K: A Major Tachykinin in Plasma and Tumor Tissues from Carcinoid Patients," <i>Biochemical and Biophysical Research Communications</i> , 1985, 131:77-83	
		WELLS, I.C., et al., "Abnormal magnesium metabolism in two rat models of genetic hypertension," <i>Can. J. Physiol. Pharmacol.</i> , 1992, 70:1225-1229.	
Examiner Signature	S. Kumar		Date Considered 7/17/03 9/2/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.